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Structured Abstract: 
1. Objective: Precise stent deployment during thoracic endovascular aortic repair of the aortic arch and proximal 
descending aorta requires transient hypotension (systolic blood pressure < 60 mm Hg during stent deployment). 
The objects of this study were to establish a protocol for vascular anesthesiologists to perform rapid ventricular 
pacing for deliberate hypotension during thoracic endovascular aortic repair, and describe the hemodynamics 
and safety of this technique in a cohort of patients. 
2. Design: This was a retrospective, observational study. 
3. Setting: Hybrid vascular operating room at a single, tertiary care center. 
4. Participants: Seven patients undergoing endovascular or hybrid repair for aneurysm or pseudoaneurysm 
involving the aortic arch in 2015-2016. 
5. Interventions: After induction of general anesthesia, a right ventricular pacing wire was placed to provide 
rapid ventricular pacing during stent graft deployment. Pacing was delivered at 175 ± 9 beats per minute. 
Vasopressors were administered by background infusion or bolus dose to maintain hemodynamic stability after 
cessation of rapid ventricular pacing. 
6. Measurements and Main Results: Characteristics of patients and endovascular or hybrid procedures were 
gathered from the electronic medical record. Patients undergoing thoracic endovascular aortic repair with rapid 
ventricular pacing were elderly (70 ± 7 years) and classified as American Society of Anesthesiologists physical 
status 3 or 4. All patients had cardiac comorbidities, most typically coronary artery disease, history of 
congestive heart failure, diastolic dysfunction, or mild to moderate valvular disease. Patients required one to 
three episodes of rapid ventricular pacing during the endovascular procedure. In all cases, rapid ventricular 
pacing yielded excellent transient hypotension and stent deployment in the aortic arch was technically 
successful. No patients had persistent hypotension, ventricular arrhythmias, or cardiac arrest after pacing. 
7. Conclusions: Rapid ventricular pacing is a useful and feasible technique for inducing deliberate, transient 
*Structured Abstract/Summary
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hypotension. In a cohort of seven patients with cardiac comorbidities, rapid ventricular pacing was well 
tolerated and facilitated technically successful endovascular repair of the aortic arch.  
 
Key Words: Thoracic endovascular aortic repair (TEVAR), rapid ventricular pacing, deliberate hypotension, 
aortic arch, hemodynamics, vascular stent graft 
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 1 
Introduction 
Thoracic endovascular aortic repair (TEVAR) is a modern approach for repair of aortic pathology including 
aneurysm, dissection, and trauma.
1
 TEVAR may spare high-risk patients a morbid open surgical repair with 
left-heart or cardiopulmonary bypass. Endovascular techniques have gained momentum with the advent of 
fenestrated and branched stent grafts that allow revascularization of major aortic branches.
2
 Aortic arch 
pathology is also amenable to TEVAR, but often requires a concurrent or staged open "debranching" procedure 
such as carotid-carotid or carotid-subclavian bypass. Debranching permits stent deployment across the origins 
of the arch vessels while maintaining perfusion to the head and upper extremities.
1
 
 Anesthetic management of TEVAR must facilitate precise deployment of stents at short proximal 
landing zones near the arch vessels.
3
 Deployment is complicated by the hydrodynamics of aortic blood flow that 
force the stent distally (“wind-sock” effect). Transient hypotension (systolic blood pressure < 60 mmHg) is 
required during deployment to limit stent migration. Various drugs have been used for this purpose,
4, 5
 but rapid 
ventricular pacing (RVP) is emerging as a preferred technique.
6
 The bulk of published data on RVP arises from 
the transcatheter aortic valve replacement (TAVR) literature, where RVP is utilized during balloon 
valvuloplasty and valve deployment. Small studies have shown efficacy and safety of RVP for TEVAR,
7-9
 but 
deaths have been reported.
10
  
 During TAVR procedures, the interventional cardiologist typically controls RVP, and the catheterization 
laboratory staff is familiar with pacing techniques. TEVAR of the aortic arch is generally performed in the 
hybrid vascular operating room or interventional suite, an environment where a cardiology team experienced in 
RVP is generally not available. Anesthesiologists, who have expertise in acute hemodynamics and the 
determinants of myocardial performance, are a natural choice to control and implement RVP. While cardiac 
anesthesiologists are likely familiar with the technique of RVP during TAVR, we expect that general 
anesthesiologists will be increasingly called upon to perform anesthesia for TEVAR as the surgical technique 
*Manuscript (without Author identifiers)
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 2 
becomes more widespread. Herein, we describe our technique for RVP, and report patient and procedural 
factors in seven cases where RVP facilitated a successful TEVAR. We hypothesized that RVP would be well 
tolerated by patients with mild to moderate cardiac disease in this cohort. 
 
Methods 
Approval was obtained from the local Committee on Human Research, and the Committee waived the need for 
informed consent. Seven operations employing RVP for TEVAR were identified from 2015-16. The medical 
chart and anesthetic records of each patient were reviewed. Details about aortic pathology and the surgical 
procedure were gathered from imaging studies and operative reports. Data on anesthetic management, 
intraoperative RVP, and hemodynamics were extracted from the electronic anesthesia record. Descriptive 
statistics were calculated using Microsoft Excel. 
 
Results 
 Patients presenting for TEVAR with RVP in this study were elderly (70 ± 7 y) and had American 
Society of Anesthesiologists (ASA) physical status classifications of 3 or 4 (Table 1). Two patients were 
classified as ASA 4E: one for a rapidly enlarging pseudoaneurysm (patient #2), and one for a ruptured, partially 
contained aortic arch pseudoaneurysm (#7). A variety of aortic arch pathologies were treated with TEVAR in 
the case series including aneurysms, enlarging or ruptured pseudoaneurysms, and penetrating atherosclerotic 
ulcer (Figure 1). One patient (#1) had an extensive thoracoabdominal aortic aneurysm extending to the arch in 
the setting of chronic type B dissection. 
 The majority of patients had cardiac comorbidities (Table 1). Coronary artery disease (CAD) was 
present in six patients, and four had been revascularized previously with coronary artery bypass grafting or 
percutaneous coronary intervention. A history of congestive heart failure (CHF) was present in three patients, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
and another (#2) had elevated B-type natriuretic peptide on admission. One patient in the study had a mildly 
depressed ejection fraction (#1). Diastolic dysfunction was present in four patients. One patient (#2) had 
pulmonary hypertension due to severe chronic obstructive pulmonary disease, and one patient had moderate 
aortic stenosis (#3). Due to an acute presentation of ruptured aneurysm, no transthoracic echocardiogram was 
available for one patient (#7). Most patients were taking a beta blocker, angiotensin converting enzyme 
inhibitor or angiotensin-receptor blocker, statin, and aspirin preoperatively (Supplemental Table). Blood 
pressure (systolic 122 ± 15 mm Hg, diastolic 76 ± 13 mm Hg) and heart rate (74 ± 13 bpm) were overall well 
controlled in the series.  
 Two patients had endovascular procedures only (#2 and 4, Table 1). Four had hybrid procedures with 
open aortic arch debranching (carotid-carotid-subclavian bypass, CCSB, Figure 2) followed by TEVAR during 
the same operation. One patient (#6) had previously undergone open debranching with deep hypothermic 
circulatory arrest - left carotid-subclavian bypass and TEVAR with RVP were performed as the second 
procedure. The term “landing zone” describes the position of the proximal stent margin relative to the arch 
vessels.
3
 Four patients had stents placed in proximal landing Zone 0 (ascending aorta or covering the 
innominate artery), two in Zone 1 (covering the left common carotid artery), and one in Zone 3 (distal to the left 
subclavian artery, Figure 1). Of the four landing Zone 0 procedures, one stent was isolated to the ascending 
aorta (#4), while the other three required arch debranching to preserve cerebral perfusion. Two patients required 
innominate snorkel stents (#3 and 7, Figure 2),
11
 while the other had previously undergone open aorto-
innominate-carotid bypass (#6).   
 To perform rapid ventricular pacing, an introducer sheath was inserted into a central vein with site 
dictated by the surgical procedure (Table 2). The right subclavian vein was preferentially used if the neck was 
planned for carotid-left subclavian bypass. A 5-French balloon-tipped Swan-Ganz bipolar pacing catheter 
(Edwards) was inserted into the right ventricle under fluoroscopic guidance. The pacing catheter tip was ideally 
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 4 
positioned at the apex of the right ventricle.
12
 In one case, oozing of blood was observed around a pacing 
catheter passed through a 9 Fr introducer (Arrow MAC). 7 Fr locking introducer sheaths (St. Jude) were found 
to be a better size match for the pacing catheter and no oozing was observed. Pacing capture thresholds ranged 
from 0.3 to 3 mA with a target of < 1 mA. The target pacing rate was 180 bpm to achieve adequate hypotension, 
a rate achieved in five (71%) of the cases. In two cases the pacing rate was adjusted down to 160-165 bpm to 
achieve consistent capture. All patients received one or two aortic stents, requiring between one and three 
episodes of RVP (some stents required balloon dilatation after deployment). In all seven cases, RVP yielded 
excellent hypotension (Supplemental Video 1 online) and accurate stent deployment. The duration of RVP was 
less than one minute in each instance. In one case (#4), the team first attempted to induce asystole with two 
doses of adenosine 12 mg IV. When this was unsuccessful, RVP was performed. 
 All patients were hemodynamically stable after RVP (Table 2). Six patients were maintained on a low 
dose vasopressor infusion (norepinephrine or phenylephrine) throughout the procedure, and no increase in 
infusion rate was required during or after RVP. One patient (#7) had sepsis prior to the start of the operation and 
required higher doses of vasopressors throughout, yet no increase was required after RVP. In one case (#5), a 
bolus of epinephrine was given prophylactically prior to RVP. No episode of RVP led to hypotension lasting 
longer than one minute, which is the minimum time resolution of the electronic anesthesia record. Blood 
pressure typically recovered to baseline in ≤ 10 seconds after discontinuation of RVP (Supplemental Video 2 
online). No significant arrhythmias were observed and defibrillation was not required. Three of seven patients 
were extubated in the OR at the end of the procedure, and one of those who had CCSB was re-intubated 
immediately post-op in the intensive care unit for airway edema. 
 
Discussion 
 TEVAR of the aortic arch is gaining in popularity and will be increasingly encountered by 
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 5 
cardiovascular and general anesthesiologists. Patients undergoing TEVAR are likely to have cardiac 
comorbidities including CAD, CHF, dysrhythmias, and valvular disease. A key aspect of successful TEVAR is 
transient hypotension during stent deployment at the proximal landing zone. Rapid and reversible reduction of 
systolic blood pressure to less than approximately 60 mm Hg helps the surgeon accurately deploy the stent and 
achieve optimal outcomes for the patient. In our cohort, RVP was well tolerated by patients with a variety of 
mild-moderate heart disease (Table 1). No direct complications of RVP were seen in this study. Data from 
TAVR indicate a 2-3% incidence of ventricular fibrillation after RVP.
13, 14
 It is therefore prudent to have ready 
access to defibrillation in the operating room. We observed no hemodynamic deteriorations at RVP cessation. 
However, cardiovascular collapse requiring cardiopulmonary bypass and deaths have been reported during 
TAVR
14
 and TEVAR
10
 procedures for patients with severe valvular disease. Titration of vasopressors to 
achieve a mean arterial pressure > 75 mm Hg has been recommended to optimize coronary perfusion prior to 
initiating RVP.
14
  
 Finally, we recommend a few practical considerations for anesthesiologists new to the technique of RVP 
for TEVAR. Careful consideration must be given to central access. Common introducer sheaths (8.5 or 9 Fr) 
used for volume resuscitation during vascular surgery may have poor size match with temporary pacing 
catheters and risk bleeding, infection, or air embolus. We recommend a small (7 Fr) dedicated introducer sheath 
for passage of the pacing catheter. The choice of central venous access site should be discussed with the 
surgeon, as access to jugular and femoral veins may be limited, particularly if carotid-subclavian bypass is 
planned. If additional central access is needed for fluids or medications, consideration should be given to 
placement of a second, dedicated central venous catheter of appropriate size. 
 Our practice is to place and test the pacing catheter in the operating room after induction of general 
anesthesia. Pacing thresholds should be checked, usually at a paced rate of 80 to 90 beats per minute, and the 
catheter position optimized if capture is not reliable at currents below 3 mA. For effective capture and pacing on 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
demand, the pacer output should be set to at least double the initial threshold (with an upper output limit of 
about 10 mA).
12
 Depending on the number of aortic stent graft components to be deployed (such as overlapping 
grafts or snorkel stents), multiple episodes of RVP may be required. It is not uncommon for pacing thresholds to 
change slightly over the course of a lengthy operation or with multiple rounds of RVP. Thus, it is important to 
achieve the best possible initial catheter position and low thresholds. After thresholds are recorded and pacer 
output is set, we recommend testing RVP at the targeted pacing rate (about 180 bpm) prior to surgical incision. 
This allows the anesthesiologist to ensure adequate systolic hypotension and assess for prompt hemodynamic 
recovery at cessation of pacing. If a patient does not tolerate RVP, it is preferable to know this fact well prior to 
the crucial moments of the surgical procedure (aortic arch stent graft deployment) and devise an alternate plan if 
necessary.  
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 9 
Figure Legends 
 
Figure 1. Schematic of aortic arch pathology in patients undergoing thoracic endovascular aortic repair 
(TEVAR) with rapid ventricular pacing (RVP) in this study. (Patient #1) Aneurysm with chronic Type B 
dissection, (#2) aneurysm enlarging due to endoleak after prior TEVAR, (#3 and #6) isolated arch aneurysm, 
(#4) ascending aortic pseudoaneurysm due to leaking patch at prior aortic cannulation site from coronary artery 
bypass grafting, (#5) penetrating atherosclerotic ulcer of the aortic arch, and (#7) ruptured aortic arch aneurysm. 
Dashed lines indicate landing zone (Z) for proximal margin of stent deployed under RVP. Arrows indicate leak 
or extravasation of blood. Lightning bolt indicates dissection. 
 
Figure 2. Intraoperative digital subtraction angiography showing completed thoracic endovascular aortic repair 
with arch debranching after stent deployment with rapid ventricular pacing (RVP) in patient #3. (A) Overview 
of arch revascularization showing arch stent graft, innominate artery snorkel stent, and carotid-carotid-
subclavian bypass (denoted by *). Right common carotid artery (R CA), left common carotid artery (L CA), and 
left subclavian artery (L SCA) are labeled. The temporary pacer wire used to deliver RVP is visible entering the 
image from the top left. (B) Close up of snorkel stent (S) extending from the ascending aortic arch into the 
innominate artery. The snorkel stent maintains flow to the carotid and subclavian arteries, and allows 
deployment of a stent graft with proximal landing zone zero. 
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Supplemental Legends 
 
Supplemental Video 1. Electrocardiogram and arterial blood pressure recordings during start of rapid 
ventricular pacing at 182 beats per minute. 
 
Supplemental Video 2. Electrocardiogram and arterial blood pressure recordings during termination of rapid 
ventricular pacing and recovery. 
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Table 1. Patient and procedure characteristics.  
Patient Age 
(y) 
Sex  BMI 
(kg/m
2
) 
ASA 
status 
Diagnosis CAD CHF EF Diastolic 
dysfunction 
Valvular 
disease 
Pulmonary 
hypertension 
Procedure Proximal 
landing 
zone
 
1 66 M 29 4 TAAA, 
chronic 
type B 
dissection 
MI, 
DES 
yes 50 % Grade 1 no no CCSB, 
arch 
TEVAR 
1 
2 66 M 22 
 
4E Thoracic 
aortic PA, 
re-do 
TEVAR 
yes elevated 
BNP 
65 % Grade 1 mild AS PASP 47 
mm Hg, RV 
pressure 
overload 
 
TEVAR 
(distal 
arch) 
3 
3 85 F 26 3 Aortic 
arch 
aneurysm 
no no 
 
70 % Grade 1-2 moderate 
AS 
PASP 34 
mm Hg 
CCSB, 
TEVAR 
(arch)
a
 
0
 
4 69 M 26 4 Ascending 
aortic PA 
CABG yes 65 % Grade 1 no no TEVAR 
(ascending 
aorta) 
0
 
Table 1
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
5 66 M 42 3 PAU, 
distal 
aortic arch 
aneurysm 
CABG yes 60 % no mild 
MR, 
mild TR 
no CCSB, 
TEVAR 
(arch) 
1 
6 72 F 29 4 Aortic 
arch PAs 
x2 
yes no 75 % no no 
 
no Left 
carotid-
subclavian 
bypass, 
TEVAR 
(arch)
b 
0
 
7 66 M 27 4E Ruptured 
aortic arch 
PA 
CABG, 
recent 
DES 
no unknown unknown unknown unknown CCSB, 
TEVAR 
(arch)
a
 
0 
Summary 
(mean ± 
s.d.) 
70 
± 7 
 29 ± 7     64 ± 9 %      
 
AS = aortic stenosis; ASA = American Society of Anesthesiologists; BMI = body mass index; BNP = B-type natriuretic peptide; CABG = 
coronary artery bypass grafting; CAD = coronary artery disease; CCSB = carotid-carotid-subclavian bypass; CHF = congestive heart failure; 
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DES = drug eluting stent; EF = ejection fraction; MI = myocardial infarction; MR = mitral regurgitation PA = pseudoaneurysm; PASP = 
pulmonary artery systolic pressure; PAU = penetrating atherosclerotic ulcer; RV = right ventricle; TAAA = thoracoabdominal aortic 
aneurysm; TEVAR = thoracic endovascular aortic repair; TR = tricuspid regurgitation.  
a 
Patient received an innominate artery snorkel stent. 
b 
Patient had prior arch debranching with aorto-innominate-left common carotid bypass via sternotomy with deep hypothermic circulatory 
arrest. 
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Table 2. Characteristics of rapid ventricular pacing and other procedural aspects. 
Patient # of 
aortic 
stents 
# RVP 
episodes 
RVP 
rate 
(min-1) 
Time 
MAP 
< 60 
(min) 
Pressor 
infusion 
(mcg/ 
min) 
Pressor 
bolus 
Other 
hypotensive 
modality 
Introducer 
for pacing 
wire 
Complications 
of vascular 
access 
Extubated in 
operating room 
1 2 1 180 1 NE 5 no no 9 Fr no No (edema) 
2 1 3 181 3 NE 2, P 35 no no 9 Fr, right IJ leak, oozing Yes 
3 2 3 165 0 NE 5-7, P 
0-20 
no no 7 Fr, right SC no Yes (re-intubated 
in ICU for edema) 
4 1 1 160 1 P 10 no Adenosine 
12 mg IV x2 
(failed) 
9 Fr, right IJ no Yes 
5 2 2 180 1 NE 3-4 Epineph-
rine 32 
mcg 
no 7 Fr, right 
femoral 
no No (rapid shallow 
breathing, obesity) 
6 2 1 180 1 NE 7 no no 7 Fr, right SC no No 
7 2 1 182 0 NE 14, 
Vaso-
pressin 
no no 7 Fr, right SC no No (edema, 
coagulopathy) 
Table 2
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28 
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0.06 
units/min 
Summary 
(mean ± 
s.d.) 
1.7 ± 
0.5 
1.7 ± 1.0 175 ± 9 1 ± 1       
 
Fr = French; ICU = intensive care unit; IJ = internal jugular; IV = intravenous; MAP = mean arterial pressure; NE = norepinephrine; P = 
phenylephrine; RVP = rapid ventricular pacing; SC = subclavian. 
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Supplemental Table. Other preoperative comorbidities, medications, and resting hemodynamics in patients presenting for TEVAR. 
Patient COPD 
(FEV1 % 
if 
known) 
Smoking 
(pack-
years) 
CKD / 
stage 
CVA Beta 
blocker 
ACEI/ARB other anti-
hypertensive 
or loop 
diuretic 
Statin Anti-
platelets 
SBP 
(mm 
Hg) 
DBP 
(mm 
Hg) 
Heart 
rate 
(bpm) 
1 yes 15 3 IPH carvedilol yes chlorthal-
idone 
yes aspirin 81 129 81 74 
2 yes 
(18%) 
100 no no no no no no no 126 83 78 
3 yes 
(normal) 
40 no no no yes amlodipine yes aspirin 81 142 87 91 
4 no 3 3 stroke metoprolol 
tartrate 
no furosemide no no 102 58 78 
5 yes 
(66%) 
40 3 no metoprolol 
tartrate 
yes HCTZ, 
amlodipine 
yes aspirin 81 111 55 79 
6 yes 50 2 stroke metoprolol 
succinate 
yes clonidine, 
HCTZ, 
amlodipine 
yes aspirin 81 138 85 81 
7 no unknown probable no metoprolol yes isosorbide yes aspirin 108 50 68 
Supplemental Table
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3 vs. 
acute 
kidney 
injury 
tartrate, 
labetalol 
infusion 
mononitrate 81, 
ticagrelor 
Summary 
(mean ± 
s.d.) 
 41 ± 34        122 
± 15 
76 ± 
13 
74 ± 
13 
 
COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume in one second; CKD = chronic kidney disease; CVA = 
cerebrovascular accident; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; IPH = intraparenchymal hemorrhage; HCTZ = hydrochlorothiazide.  
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